

PROSPECTS FOR DIGITAL PCR IN ABSOLUTE QUANTIFICATION OF DNA

LESSONS LEARNED FROM HIV CURE AND FOLLOW-UP


Ward De Spiegelaere, 5th qPCR & Digital PCR congress









THE HIV/AIDS PANDEMIC




HIV TREATABLE, BUT INCURABLE







HOW BIG IS THE HIV RESERVOIR





Malatinkova, E., Spiegelaere, W.D., Bonczkowski, P., Kiselinova, M., Vervisch, K., Trypsteen, W., Johnson, M., Verhofstede, C., Looze, D., Murray, C., Loes, S.K., Vandekerckhove, L., 2015. Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. eLife 4, e09115.



DPCR IS MORE PRECISE THAN QPCR

Comparison of ddPCR versus seminested qPCR for HIV DNA quantification


Coeficient of Variation (CV) between triplicates

	n	replicates	CV ddPCR	CV qPCR	Fold difference
Standard curve	7	3	14%	43%	3
Patient samples	17	3	8%	29%	3.5



<u>ACCURACY</u>


No significant bias compared to qPCR on HIV DNA measurement






DPCR AND INHIBITION

dPCR outperforms qPCR comparing inhibitory substances (SDS, EDTA and Heparin)








DPCR AND INHIBITION: MISMATCHES


Probe mismatches



Lower fluorescence would harm qPCR but less harm to ddPCR



SENSITIVITY: FALSE POSITIVES IN DDPCR





DPCR PERFORMANCE


-Better accuracy and precision

-Less refractory to inhibition



-More sensitive?





When to use dPCR or qPCR depends on the question:

Template present?

 \rightarrow

go for standar PCR or nested

How much?


 \rightarrow

go for digital PCR




SETTING A TRESHOLD FOR DIGITAL PCR

GHENT UNIVERSITY



DATA DRIVEN METHODS:HARD TRESHOLDING

Do not use parametric distributions!






www.ddpcrquant.ugent.be www.dPCR.ugent.be

Trypsteen et al., Anal Bioanal Chem (2015) 407:5827-34


BACKGROUND SHIFT






DDPCRQUANT

ddpcRquant





Sample Analysis

Summary

Replicate Analysis

NTC Threshold Analysis



www.ddpcrguant.ugent.be

Trypsteen et al., Anal Bioanal Chem (2015) 407:5827-34

SOFT TRESHOLDING (MODELLING THE RAIN)







Model-Based Classification for Digital PCR: Your Umbrella for Rain

Bart K. M. Jacobs,**^{†®} Els Goetghebeur,[†] Jo Vandesompele,^{‡,¶,§} Ariane De Ganck,[¶] Nele Nijs,[¶] Anneleen Beckers,[¶] Nina Papazova,[∥] Nancy H. Roosens,[∥] and Lieven Clement**^{†,§}

Supporting Information

ABSTRACT: Standard data analysis pipelines for digital PCR estimate the concentration of a target nucleic acid by digitizing the end-point fluorescence of the parallel micro-PCR reactions, using an automated hard threshold. While it is known that misclassification has a major impact on the concentration estimate and substantially reduces accuracy, the uncertainty of this classification is typically ignored. We introduce a model-based clustering method to estimate the probability that the target is present (absent) in a partition conditional on its observed fluorescence and the distributional shape in no-template control samples. This methodology acknowledges the inhance transactions of the absolute and appropriate a partial processor.







[†]Department of Applied Mathematics, Computer Science and Statistics, Ghent University, Ghent, Belgium

[‡]Center for Medical Genetics Ghent (CMGG), Ghent University, Ghent, Belgium

[¶]Biogazelle, Zwijnaarde, Belgium

[§]Bioinformatics Institute Ghent From Nucleotides to Networks (Big N2N), Ghent University, Ghent, Belgium

Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium


MEASURING THE HIV RESERVOIR

- 1) HIV cure research
 - Monitoring efficacy of experimental treatment
 Question: does the DNA reservoir correlate with the replication competent reservoir?
- 2) Current clinical follow-up
 - Stratisfying high risk vs low risk
 - Regimen change to monotherapy



DDPCR IN HIV CURE STUDIES?

1) Validation of HIV DNA as a relevant marker for the HIV reservoir Comparison with an *ex vivo* viral outgrowth assay



2) Analysis of HIV DNA levels in cure studies

Clinical Infectious Diseases

MAJOR ARTICLE











Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection

TOTAL HIV DNA CORRELATES WITH VIRAL OUTGROWTH











SHORT-COURSE TOLL-LIKE RECEPTOR 9 AGONIST TREATMENT





From: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection Clin Infect Dis. 2017;64(12):1686-1695. doi:10.1093/cid/cix201

SHORT-COURSE TOLL-LIKE RECEPTOR 9 AGONIST TREATMENT






From: Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection Clin Infect Dis. 2017;64(12):1686-1695. doi:10.1093/cid/cix201

IN FOLLOW-UP

Patient stratification





MONOTHERAPY: PROTEA STUDY

Randomized clinical trial (NCT01448707) **Enpoint:** HIV-1 RNA < W48 W96 50 copies/mL **HIV-1** infected patients Triple therapy 116/136 patients First-line treatment DRV/r 800/100mg +2 NRTIs (85%) Viral load (VL) undetectable CD4 nadir >100 cells/mm³ Monotherapy CD4 at baseline ≥200 103/137 patients DRV/r 800/100mg (75%)cells/mm³

- → Switch to monotherapy shows lower efficacy but is safe
- → Can we predict this outcome upfront?



PROTEA SUBSTUDY

Patient characteristics




	Undectable VL	Detected VL	Failers	
N	27	25	25	
Age, years, mean (SD)	45 (10.8)	42 (9.3)	48 (8.8)	
Male sex, N (%)	21 (77.8)	20 (80)	20 (80)	
CD4-nadir, cells/mm ³	245 (204-309)	250 (190-357)	217 (169-311)	
CD4 at baseline, cells/mm ³	585 (399-644)	633 (522 - 796)	570 (447 - 765)	
Time on cART, years	5.7 (3.3-9.45)	4.5 (2.8-7.4)	4.6 (2.4-8.3)	



Data documented as median (Q1,Q3), unless stated otherwise.

TOTAL HIV-1 DNA

Level of total HIV-1 DNA in patients on DRV/r monotherapy






*****: p<0,05

TOTAL HIV-1 DNA

Cut-off of 2.2 log total HIV DNA/106PBMCs.

DRV/r monotherapy: 66% of patients success rate: 99%.





CONCLUSION

dPCR in HIV research

- Good performance for HIV DNA quantification
- Promising tool in current HIV follow-up
- Validation in HIV cure setting still requiered







www.dPCR.ugent.be

Linos Vandekerckhove

Ward De Spiegelaere Magdalena Sips

Sofie Rutsaert Wim Trypsteen

Karen Vervisch

Laura De Clercq

Maja Kiselinova

Pawel Bonczkowski

Sam Kint

Eva Malatinkova

Marie-Angélique De Scheerder

Clarissa Van Hecke Basiel Cole

Dorien Vanderroost Jon Huyghe

Collaborators:

University College LondonSabine Kinloch-de Loes

University of Utrecht

Prof. Monique Nijhuis Prof. Annemarie Wensing Kobus Bosman Petra Vanham

Ghent University

Prof. Chris Verhofstede

The AIDS Reference Center Prof Dirk Vogelaers Prof Chris Verhostede











